Seidman A D, Hudis C A, Norton L
Breast and Gynecologic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Semin Oncol. 1995 Aug;22(4 Suppl 8):3-8.
The novel chemotherapeutic agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has received more attention than perhaps any other drug in the past two decades in its development for the treatment of breast cancer. Its unique mechanism of action, demonstrated safety profile, and significant antitumor activity in thousands of patients treated in clinical trials thus far have led to recent US Food and Drug Administration approval of its use against chemotherapy-refractory metastatic breast cancer. This report will summarize the series of clinical investigations with paclitaxel in patients with metastatic breast cancer that have been completed over the past 3 years at Memorial Sloan-Kettering Cancer Center and address present and future avenues of research.
新型化疗药物紫杉醇（泰素；百时美施贵宝公司，新泽西州普林斯顿）在过去二十年中用于乳腺癌治疗的研发过程中，受到的关注可能超过了其他任何药物。其独特的作用机制、已证实的安全性以及在迄今为止数千名接受临床试验的患者中所展现出的显著抗肿瘤活性，促使美国食品药品监督管理局最近批准其用于治疗化疗难治性转移性乳腺癌。本报告将总结过去三年在纪念斯隆凯特琳癌症中心完成的针对转移性乳腺癌患者使用紫杉醇的一系列临床研究，并探讨当前及未来的研究方向。
